Prediabetes Market: Current Analysis and Forecast (2025-2033)

Prediabetes is a diabetes-like condition in which the prediabetes symptoms include a blood glucose level that is above the normal range but below the thresholds considered indicative of type 2 diabetes. According to the American Diabetes Association (ADA), glycated hemoglobin (A1C) test results between 5.7% and 6.4% come in the prediabetes range. Prediabetes points to poor outcomes of glucose tolerance or even insulin sensitivity, which can lead to the development of diabetes, heart conditions, and stroke. Prediabetes can have no visible signs, and, therefore, individuals may be unaware of the condition for several years and require frequent checkups. Some of the signs of prediabetes are obesity, lack of physical activity, poor diet, heredity, and increasing age. Thus, a healthy prediabetes diet, regular physical activity, and weight loss may help to prevent the development of diabetes, specifically if one has been diagnosed with prediabetes.

The Prediabetes market is set to show a growth rate of about 10.02% during the forecast period (2025-2033F). The prediabetes market is significantly progressing because of the increasing rates of its prevalence, the augmentation of awareness about the disease, and the changing trends in the global focus on preventive medicine. A sedentary lifestyle, improper diet, and increased prevalence of obesity have been emerging factors for the rise in the incidence of prediabetes, primarily in urban communities. Growing awareness of the risky consequences of untreated prediabetes, such as the development of type 2 diabetes and cardiovascular diseases, is driving early intervention strategies among patients. Moreover, frequent physical checkups and modifications in lifestyle represent two aspects that governments and other healthcare-related bodies are continuously encouraging, thus driving the market growth.

Based on product type, the market is segmented into diagnostics & devices, pharmaceuticals & therapeutics, nutraceutical & functional foods, and others. Among these, the diagnostics & devices segment has the highest market share. This dominance is due to the growing number of tools for early detection of diabetes, heightened consciousness among people about prediabetes medications and management, and the increased use of blood glucose monitors, HbA1c testing kits, and CGM devices. However, the nutraceuticals & functional foods sector is expected to grow at the fastest rate in the future, due to the shift towards using natural healthcare solutions, and the use of dietary supplements and functional foods to control blood sugar levels.

Based on the age group category, the market is segmented into children, adults, and the elderly. Out of these, the adult segment has the biggest market share. This is because the adult population is engaged in sedentary lifestyles, consumes unhealthy foods, and experiences increased stress levels, which increases the risk of prediabetes. However, the fastest-growing segment is expected to be the elderly segment. Since age is a common predictor of glucose intolerance and insulin resistance, prediabetes treatment is expected to stem from the growing geriatric population across the globe.

Based on the end-user category, the global market is categorized into hospitals & clinics, diagnostic centers, homecare settings, and others. Among these, the hospitals & clinics segment has the largest market share. Major factors are increased patients' visits to hospitals, availability of enhanced diagnostic laboratories, and healthcare practitioners' specialization in early identification and control of prediabetes. However, the Homecare Settings segment is expected to show the highest CAGR in the future. This is due to the increase in the use of personal health monitoring devices, knowledge of preventive care, and developments in telemedicine and remote patient monitoring facilities.

For a better understanding of the market adoption of therapeutics solutions for prediabetes, the market is analyzed based on its worldwide adoption in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Among these, the North America region holds a significant market share due to its high disease prevalence, well-established healthcare infrastructure, and strong government initiatives promoting early screening and preventive care. However, the Asia-Pacific Prediabetes market is moving forward due to rapid urbanization, increasing obesity rates, changing lifestyles, and growing healthcare investments.

Some major players running in the market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthineers, Ascensia Diabetes Care, Omada Health, Noom, Inc., Eli Lilly and Company, PharmaLinea, Oramed, and Bayer AG.